VEGF receptor kinase inhibitors: phthalazines, anthranilamides and related structures
- 14 June 2005
- journal article
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 15 (6), 647-658
- https://doi.org/10.1517/13543776.15.6.647
Abstract
Inhibition of vascular endothelial growth factor receptor (VEGFR) signalling, using either antibodies or small molecule inhibitors of the VEGFR kinase domain, has become a major area of research in oncology. The phthalazine PTK787/ZK222584, first published in the literature in 1998, is one of the most advanced VEGFR inhibitors in the clinic. This paper provides an update on the patenting activity related to the phthalazine class. In addition, newer kinase inhibitor pharmacophores derived from this class (e.g., anthranilamides) will be reviewed.Keywords
This publication has 14 references indexed in Scilit:
- A case study of the gefitinib patent estateExpert Opinion on Therapeutic Patents, 2004
- Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude miceClinical & Experimental Metastasis, 2004
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I StudiesJournal of Clinical Oncology, 2003
- Therapies directed at vascular endothelial growth factorExpert Opinion on Investigational Drugs, 2002
- Small Molecule Inhibitors of KDR (VEGFR-2) Kinase: An Overview of Structure Activity RelationshipsCurrent Topics in Medicinal Chemistry, 2002
- Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agentsExpert Opinion on Investigational Drugs, 2002
- CGP 79787D (PTK787/ZK222584), CGP 84738, NVP-AAC789, NVP-AAD777 and related 1-anilino-(4-pyridylmethyl)phthalazines as inhibitors of VEGF- and bFGF-induced angiogenesisDrugs of the Future, 2002
- Inhibition of Growth and Metastasis of Human Pancreatic Cancer Growing in Nude Mice by PTK 787/ZK222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine KinasesCancer Biotherapy & Radiopharmaceuticals, 2001
- New Anilinophthalazines as Potent and Orally Well Absorbed Inhibitors of the VEGF Receptor Tyrosine Kinases Useful as Antagonists of Tumor-Driven AngiogenesisJournal of Medicinal Chemistry, 2000
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993